Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)

By sjmartinez • April 25, 2025

Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, Saygin D, Marder G, Venuturupalli S, Dellaripa PF, Danoff SK, Doyle T, Hunninghake GM, Lee JS, Fischer A, Falk J, Johnson C, Koontz D, Ascherman DP, Oddis CV. Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD). Rheumatology (Oxford). 2025 Apr 24:keaf218. doi: 10.1093/rheumatology/keaf218. Epub ahead of print. PMID: 40272902.

Tags: abatacept, anti-synthetase syndrome, Cedars Sinai DoM, Idiopathic inflammatory myopathy, interstitial lung disease, placebo-controlled trial, Publications, Pulmonary, Critical Care & Sleep Medicine, randomized, Rheumatology

Related Posts

Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries[...]

Sexually Distinct Multi-Omic Responses to Progressive Endurance Exercise Training in the Rat Lung – Findings from MoTrPAC

Many GM, Sagendorf TJ, Mitchell H, Sanford JA, Cohen S, Misra R, Estevao I, Díaz Ludovico I, Gaul DA, Lindholm ME, Ushakumary MG, Pino J,[...]

Surveying patients to assess timeliness of cancer diagnosis

O'Hanlon CE, Berdahl C, Ye F, Ohana E, Tolpadi A, Bradley MA, Marsolais E, Ptacek M, Henreid AJ, Anhang Price R. Surveying patients to assess[...]